

***Trust Logo***

**<GLH region name>**

**NHS Genomic Laboratory Hub**

|  |  |  |
| --- | --- | --- |
| ***Head of Department***  *Name* |  | *Local Genetics Service*  *Local Trust*  *Address*  *Address*  *Post Code*  *Web site address* |
| General Enquiries: *telephone contact*  Email: *generic email address* |
|  | | |

**GENOMIC LABORATORY REPORT**

|  |  |  |
| --- | --- | --- |
| Dr xxx | **Patient Name:** | **Jane DOE** |
| Consultant | Gender: | Female |
| <<Hospital address>> | Date of Birth: | 14 Jan 1968 |
| NHS No: | 123 456 7890 |
| Hospital No: | NK |
| Your ref: | GC12345 |

**Reason for testing**

Diagnostic testing. <<Referral reason>>. Patient phenotype / HPO terms

|  |
| --- |
| **Result summary** |
| **A hereditary (germline) genetic cause for the patient’s cancer has not been identified** |

**Result**

No pathogenic variants were detected in the *BRCA1*, *BRCA2* and *PALB2* genes.

**Implications**

This testing excludes >99% of pathogenic variants in these genes. This result does not exclude a diagnosis of autosomal dominant hereditary breast and ovarian cancer.

**Recommended action**

None

Date issued: <AUTHORISEDDATE> Authoriser: Clinical Scientist

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**TECHNICAL INFORMATION**

|  |  |
| --- | --- |
| **Sequence analysis** | **Dosage analysis** |
| No pathogenic variants detected | No copy number variants detected |

**Test methodology**

1. Genes screened in the panel: *BRCA1* - NM\_007294.3; *BRCA2* - NM\_000059.3; *PALB2* – NM\_024675.3
2. Enrichment method: Agilent SureSelect Custom Design and sequenced on the Illumina platform with a sensitivity of at least 95%.The target region of those selected transcripts is covered to a minimum read depth of 30x.
3. Screening for large deletions and duplications is performed using comparative depth of coverage of NGS data. Deletions/duplications are confirmed by Multiplex Ligation-Dependent Probe Amplification (MRC-Holland).
4. Variant classification according to the American College of Medical Genetics and Genomics (ACMG)1 and Association for Clinical Genomic Science (ACGS) 2020 guidelines2 and Cancer Variant Interpretation Group-UK consensus specification for Cancer Susceptibility Genes3 ([http://www.canvaruk.org](http://www.canvaruk.org/)/)

1Richards *et al.* (2015) Genetics in Medicine 17:405-24. (PMID 25741868)

2www.acgs.uk.com/quality/best-practice-guidelines

3 Garrett et al (2020) J Med Genet (PMID: 32170000)

1. Only relevant results are shown; full details of methods and results, including benign/likely benign variants and variants of uncertain clinical significance, are stored on file and are available on request.

**Sample details**

|  |  |  |  |
| --- | --- | --- | --- |
| Your lab ref: | 122001180 |  |  |
| Sample ID: | 1234567 | Sample collected: | 05 Jun 2020 |
| Sample type: | DNA from peripheral blood | Sample received: | 05 Jun 2020 |